Evidence map›Paper›PMID 34604100›Full record

ArticleFrontiers in oncology2021

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms.

Ken-Hong Lim, Shinobu Matsuura, Bing Xu

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ken-Hong LimDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei City, Taiwan.
Shinobu MatsuuraDepartment of Medicine-Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States.
Bing XuDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.

Funding

A path to thrombosis in primary myelofibrosisR01HL136363 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2018 to 2021
$1.9M
The bone marrow extracellular matrix: scaffold of hematopoiesisK01OD025290 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MATSUURA, SHINOBU · 2019 to 2023
$611k
NHLBI NIH HHS R01 HL136363NIH HHS K01 OD025290
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CALRchronic myeloid leukemiaMPLmyeloproliferative neoplasmstyrosine kinase inhibitor

Identifiers

PMID34604100
PMCPMC8479092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.